somaxon pharmaceuticals
Events
Home > Investor Relations > Events
Events
Upcoming Events
Details on upcoming events are not yet available. Please click here to be notified of all upcoming events.

Past Events
Jefferies 2010 Global Life Sciences Conference
Jun 10, 2010 11:30 AM ET
Listen to webcast Webcast
View Presentation
Somaxon Pharmaceuticals 2010 First Quarter Financial Results Conference Call
May 11, 2010 4:30 PM ET
Listen to webcast Webcast
Somaxon Announces FDA Approval of Silenor for the Treatment of Insomnia
Mar 18, 2010 9:00 AM PT
Listen to webcast Webcast
Somaxon Pharmaceuticals 2009 Third Quarter Financial Results Conference Call
Nov 5, 2009 1:30 PM PT
Listen to webcast Webcast
The 8th Annual BIO Investor Forum
Oct 28, 2009 3:00 PM PT
Listen to webcast Webcast
Somaxon Pharmaceuticals 2009 Second Quarter Financial Results Conference Call
Aug 6, 2009 4:30 PM ET
Listen to webcast Webcast
Somaxon Pharmaceuticals 2009 First Quarter Financial Results Conference Call
May 7, 2009 1:30 PM PT
Listen to webcast Webcast
Somaxon Pharmaceuticals to Report 2008 Fourth Quarter And Full Year Financial Results
Mar 12, 2009 4:30 PM ET
Listen to webcast Webcast
Somaxon Special Conference Call
Feb 26, 2009 1:30 PM PT
Listen to webcast Webcast
FDA Extends Review of Somaxon Pharmaceuticals New Drug Application for Silenor Conference Call
Nov 24, 2008 9:00 AM ET
Listen to webcast Webcast

Forward-Looking Statements

Somaxon cautions you that statements included in the company's conference calls, press releases and other materials posted on, or available through, this website that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Somaxon that any of its plans will be achieved. Actual results may differ materially from those discussed in the conference calls, press releases and other materials posted on, or available through, this website due to the risks and uncertainties inherent in Somaxon's business including, without limitation: the progress and timing of its clinical trials and regulatory approval process; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its product candidates; unexpected adverse side effects or inadequate therapeutic efficacy of its product candidates that could delay or prevent regulatory approval, product development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its product candidates; and other risks detailed in Somaxon's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K for its most recently completed fiscal year. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Somaxon undertakes no obligation to revise or update such statements to reflect events or circumstances after the date made. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.